Committee Report
Clinical Alert: Intraocular Use of Epinephrine to Maintain Mydriasis during Cataract Surgery
December 2017
Author: Richard S. Hoffman, MD
You must be logged in to view this content

This resource is only available for ASCRS Members. Please log in using the teal "Login" button in the top right-hand corner to log in.

Clinical Alert Details

An alteration in the formulation of epinephrine from one of the more common sources of preservative-free epinephrine has contributed to a shortage or impending shortage of this product for ophthalmologists. In January 2017, PAR Pharmaceutical updated and began shipping the new formulation of epinephrine which in addition to containing 0.457 mg of sodium metabisulfite, will also contain 2.25 mg of tartaric acid per ml.

We use cookies to measure site performance and improve your experience. By continuing to use this site, you agree to our Privacy Policy and Legal Notice.